{
  "zip": "1560",
  "sector": "Healthcare",
  "fullTimeEmployees": 712,
  "longBusinessSummary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.",
  "city": "Copenhagen",
  "phone": "45 70 20 27 28",
  "country": "Denmark",
  "companyOfficers": [],
  "website": "http://www.genmab.com",
  "maxAge": 1,
  "address1": "Kalvebod Brygge 43",
  "industry": "Biotechnology",
  "previousClose": 438.42,
  "regularMarketOpen": 437.92,
  "twoHundredDayAverage": 370.2887,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 456.83,
  "navPrice": null,
  "averageDailyVolume10Day": 1712,
  "totalAssets": null,
  "regularMarketPreviousClose": 438.42,
  "fiftyDayAverage": 398.54517,
  "trailingAnnualDividendRate": null,
  "open": 437.92,
  "averageVolume10days": 1712,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.593973,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 430.08,
  "priceHint": 2,
  "currency": "USD",
  "trailingPE": 127.39264,
  "regularMarketVolume": 247,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 29722044416,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 633,
  "priceToSalesTrailing12Months": null,
  "dayLow": 430.08,
  "ask": 0,
  "ytdReturn": null,
  "askSize": 0,
  "volume": 247,
  "fiftyTwoWeekHigh": 456.83,
  "forwardPE": 69.74503,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 159.45,
  "bid": 0,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": 0,
  "dayHigh": 456.83,
  "exchange": "PNK",
  "shortName": "GENMAB AS",
  "longName": "Genmab A/S",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": true,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "GNMSF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_665704",
  "uuid": "bc5ee846-4743-31f0-a550-ee0aa32fbaca",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0.51224,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": 6.55,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 65545700,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": 17.998,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.46882,
  "netIncomeToCommon": null,
  "trailingEps": 3.586,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": 25.382265,
  "heldPercentInsiders": 0.046350002,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1601424000,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 64632725,
  "enterpriseValue": 28656371712,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": -0.013,
  "dateShortInterest": null,
  "pegRatio": 81.88,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 437.92,
  "logo_url": "https://logo.clearbit.com/genmab.com"
}